Correlation between Neutrophil-to-Lymphocyte Ratio and Pretreatment Magnetic Resonance Imaging and Their Predictive Significance in Cervical Carcinoma Patients Referred for Radiotherapy
Table 3
Univariate analysis for overall survival (OS) and progression-free survival (PFS).
Variable
n
OS (months)
value
PFS (months)
value
Mean (SE)
95% CI
Mean (SE)
95% CI
Age
≤50 years
34
46.42 (3.05)
40.44–52.40
0.451
42.22 (3.45)
35.45–48.98
0.253
>50 years
44
57.04 (3.16)
50.84–63.24
54.75 (3.38)
48.12–61.38
FIGO stage
IB-IIB
36
53.98 (3.78)
46.58–61.38
0.279
47.02 (4.41)
38.39–55.66
0.109
IIIA-IIIB
7
48.89 (6.65)
35.85–61.93
40.75 (4.88)
31.19–50.30
IIIC-IVA
35
55.59 (2.42)
50.85–60.32
54.05 (2.77)
48.63–59.47
Tumor diameter
<20 mm
9
50.20 (6.85)
36.77–63.63
0.676
45.75 (6.27)
33.46–58.03
0.840
≥20 mm, < 40 mm
28
58.59 (4.16)
50.43–66.74
52.19 (4.95)
42.49–61.89
≥40 mm
41
50.63 (2.90)
44.94–56.32
49.01 (3.23)
42.68–55.34
Pelvic lymph node metastasis
Negative
56
54.54 (3.09)
48.48–60.60
0.496
50.25 (3.27)
43.84–56.66
0.177
Positive
22
50.02 (2.79)
44.55–55.48
49.91 (2.87)
44.28–55.54
Vagina invasion
Negative
18
55.51 (2.77)
50.69–60.94
0.316
53.21 (3.34)
46.66–59.76
0.308
Positive
60
54.26 (3.33)
47.73–60.78
51.06 (3.33)
44.54–57.58
Uterine body invasion
Negative
53
59.16 (2.67)
53.93–64.38
0.013※
54.26 (3.10)
48.19–60.34
0.253
Positive
25
40.49 (3.53)
33.56–47.41
39.50 (3.89)
31.88–47.11
Parametrial invasion
Negative
67
57.07 (2.82)
51.54–62.59
0.047※
54.24 (2.87)
48.62–59.87
0.042※
Positive
11
38.82 (6.43)
26.21–51.42
34.26 (6.96)
20.63–47.90
ADC value
≤0.78 × 10−3 mm2/s
39
51.50 (3.28)
45.08–57.93
0.426
48.29 (3.72)
41.01–55.57
0.639
>0.78 × 10−3 mm2/s
39
54.89 (4.34)
46.38–63.40
51.74 (4.04)
43.83–59.65
Leukocyte count
<4000 n/μl
11
32.23 (3.26)
25.84–38.62
0.452
25.39 (4.37)
16.82–33.95
0.067
4000–10000 n/μl
57
55.86 (3.44)
49.12–62.60
54.53 (3.04)
48.57–60.48
>10000 n/μl
10
47.13 (7.21)
33.00–61.26
46.35 (7.58)
31.49–61.21
Neutrophil count
<2000 n/μl
8
33.98 (3.20)
27.72–40.24
0.388
23.61 (3.69)
16.39–30.83
0.442
2000–7000 n/μl
59
55.85 (3.44)
49.11–62.59
53.72 (3.07)
47.70–59.74
>7000 n/μl
11
44.52 (7.01)
30.78–58.26
43.81 (7.31)
29.49–58.13
Lymphocyte count
<1500 n/μl
25
39.30 (2.68)
34.04–44.56
0.219
35.76 (3.56)
28.79–42.74
0.050
1500–2500 n/μl
42
54.25 (2.40)
49.53–58.96
51.68 (2.86)
46.07–57.29
>2500 n/μl
11
57.62 (5.30)
47.23–68.01
57.16 (5.75)
45.88–68.43
NLR
≤3.87
63
58.51 (2.96)
0.001※※
55.88 (2.85)
50.30–61.46
0.002※※
>3.87
15
55.63 (2.67)
31.32 (5.86)
19.84–42.79
CI: confidence interval; OS: overall survival; PFS: progression-free survival; ADC: apparent diffusion coefficient; FIGO: International Federation of Gynecology and Obstetrics; NLR: neutrophil-to-lymphocyte ratio. ※;※※.
